Key Takeaways
- • Aiolos Bio and two of its founders filed a motion in Delaware Chancery Court seeking to block a Massachusetts lawsuit brought by a former Tier1 Bio stockholder regarding the 2023 dissolution of Tier1 and Aiolos' subsequent $1 billion acquisition by GlaxoSmithKline.
- • The defendants argue the plaintiff agreed to resolve all corporate disputes exclusively through Delaware courts, making the Massachusetts litigation a breach of contractual jurisdiction provisions.
- • The lawsuit stems from Tier1 Bio's 2023 dissolution, which preceded Aiolos' $1 billion sale to GSK, indicating potential valuation or governance disputes tied to the earlier corporate restructuring.
- • The case centers on forum selection clauses and their enforceability in multi-state transactions involving pharmaceutical asset acquisitions.
Summary
Aiolos Bio Inc. and two of its founders have moved to dismiss a Massachusetts lawsuit filed by a former Tier1 Bio Inc. shareholder, seeking intervention from the Delaware Chancery Court to prevent the litigation from proceeding outside Delaware jurisdiction. The motion, filed on September 1, 2026, challenges the plaintiff's right to pursue claims in Massachusetts rather than Delaware courts.
The underlying dispute traces to Tier1 Bio's dissolution in 2023, followed by Aiolos' $1 billion sale to pharmaceutical giant GlaxoSmithKline. The former Tier1 stockholder initiated legal action in Massachusetts, reportedly challenging elements of the corporate restructuring or the terms under which the GSK transaction was executed. Aiolos and the two founders argue that the shareholder executed agreements containing exclusive forum selection clauses mandating that all corporate governance and dissolution-related disputes be litigated exclusively in Delaware courts.
The defendants contend that the plaintiff's decision to file in Massachusetts represents a violation of contractual terms and procedural agreements established during Tier1's dissolution. By petitioning the Delaware Chancery Court—a forum typically favorable to enforcing contractual provisions in corporate matters—Aiolos seeks to consolidate jurisdiction and potentially resolve the dispute under Delaware's well-established corporate law framework.
This motion underscores the tension between contractual forum selection clauses and the practical ability of shareholders to challenge corporate transactions across multiple jurisdictions. The case carries implications for life sciences M&A practice, particularly regarding how dissolution agreements and post-acquisition disputes are governed when multiple states have potential claims.
The underlying dispute traces to Tier1 Bio's dissolution in 2023, followed by Aiolos' $1 billion sale to pharmaceutical giant GlaxoSmithKline. The former Tier1 stockholder initiated legal action in Massachusetts, reportedly challenging elements of the corporate restructuring or the terms under which the GSK transaction was executed. Aiolos and the two founders argue that the shareholder executed agreements containing exclusive forum selection clauses mandating that all corporate governance and dissolution-related disputes be litigated exclusively in Delaware courts.
The defendants contend that the plaintiff's decision to file in Massachusetts represents a violation of contractual terms and procedural agreements established during Tier1's dissolution. By petitioning the Delaware Chancery Court—a forum typically favorable to enforcing contractual provisions in corporate matters—Aiolos seeks to consolidate jurisdiction and potentially resolve the dispute under Delaware's well-established corporate law framework.
This motion underscores the tension between contractual forum selection clauses and the practical ability of shareholders to challenge corporate transactions across multiple jurisdictions. The case carries implications for life sciences M&A practice, particularly regarding how dissolution agreements and post-acquisition disputes are governed when multiple states have potential claims.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.